News Industry News FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy May 13, 2019
News Industry News FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis May 06, 2019